June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Modified Exosomes for Extended Intravitreal Drug Delivery
Author Affiliations & Notes
  • Emmanuel Ho
    Pharmacy, University of Waterloo Faculty of Science, Waterloo, Ontario, Canada
    Centre for Eye and Vision Research Limited, Hong Kong, Hong Kong
  • Derek Chen
    Pharmacy, University of Waterloo Faculty of Science, Waterloo, Ontario, Canada
    Centre for Eye and Vision Research Limited, Hong Kong, Hong Kong
  • Yusheng Zhao
    Pharmacy, University of Waterloo Faculty of Science, Waterloo, Ontario, Canada
  • Praveen Nekkar Rao
    Pharmacy, University of Waterloo Faculty of Science, Waterloo, Ontario, Canada
  • Footnotes
    Commercial Relationships   Emmanuel Ho, None; Derek Chen, None; Yusheng Zhao, None; Praveen Nekkar Rao, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1208. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Emmanuel Ho, Derek Chen, Yusheng Zhao, Praveen Nekkar Rao; Modified Exosomes for Extended Intravitreal Drug Delivery. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1208.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Intravitreal injection (IVI) is the only feasible method of drug delivery to the retina. However, IVIs are only suitable for drugs with large therapeutic indices and long half-lives, as rapid diffusion mediates clearance and loss of therapeutic effects. There is a need to improve IVI systems to reduce injection frequency and allow for delivery of drugs with unfavorable properties. Nanoparticle encapsulation of a drug can improve drug solubility, stability, and half-life. Exosomes are cell-derived vesicles that can be used as drug delivery nanoparticles. Hyaluronan is an aminoglycan found in high concentrations in the vitreous of the eye. Conjugation of hyaluronan-binding moieties is one strategy that can be used to restricting diffusion and improve the intravitreal half-life of therapeutics. The objectives are to design and evaluate hyaluronan-binding peptides using in silico modeling and in-vitro modeling. Then, peptides are evaluated for their ability to restrict exosomes drugs using an in vitro diffusion model. We hypothesize that presence of hyaluronan solution will decrease the diffusion rate of peptide conjugated exosomes, and thus may be useful for increasing the half-life of therapeutics for retinal drug delivery.

Methods : Exosomes will be isolated from retinal cell culture using differential ultracentrifugation. Exosome cell uptake into retinal cells will be evaluated qualitatively by fluorescence microscopy. Drug loading and release will be evaluated following loading of exosomes with model small molecule drugs. Hyaluronan-binding peptides will be designed using molecular docking techniques. Candidate peptides will be conjugated to the surface of exosomes using click chemistry. Exosome diffusion rates will be evaluated using a diffusion cell model.

Results : Exosomes were positive for CD63, had a mean diameter of 85.0 nm, and had round morphology as imaged by STEM. Molecular docking identified several peptides with strong interaction to hyaluronan. Exosomes displayed time depending uptake into ARPE19 cells in culture.

Conclusions : Exosomes derived from retinal cell culture are a promising nanoparticles system for IVI as they have favorable properties for drug delivery. Molecular docking is a useful tool to design peptide ligands. Future work should evaluate the extent of drug loading and release and evaluate the effect of peptides on diffusion through hyaluronan solution.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×